Xenon Pharmaceuticals (XENE) Files Mixed Shelf Registration Statement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Xenon Pharmaceuticals (XENE) Prices 8.47M Share Offering at $29.50/sh
October 6, 2021 5:44 AM EDTXenon Pharmaceuticals Inc. (Nasdaq: XENE), a clinical stage biopharmaceutical company, today announced the pricing of its underwritten public offering of 8,474,577 common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase up to 1,694,915 common shares pursuant to its existing shelf registration statement. The common shares are being offered at a public offering price of $29.50 per common share and the pre-funded warrants are being offered at a price of $29.4999 per pre-funded warrant. The gross proceeds to Xenon from the offering, before deducting underwriting discounts and commissions and other offering... More
Xenon Pharmaceuticals (XENE) PT Raised to $50 at Jefferies
October 4, 2021 11:23 AM EDTJefferies analyst Andrew Tsai raised the price target on Xenon Pharmaceuticals (NASDAQ: XENE) to $50.00 (from $28.00) while maintaining a Buy rating.
... MoreXenon Pharmaceuticals (XENE) PT Raised to $45 at Wedbush, Following Clinical Business Update
October 4, 2021 11:04 AM EDTWedbush analyst Laura Chico raised the price target on Xenon Pharmaceuticals (NASDAQ: XENE) to $45.00 (from $24.00) while maintaining a Outperform rating.
... MoreXenon Pharmaceuticals (XENE) PT Raised to $45 at Guggenheim, Following Clinical Business Update
October 4, 2021 10:51 AM EDTGuggenheim analyst Yatin Suneja raised the price target on Xenon Pharmaceuticals (NASDAQ: XENE) to $45.00 (from $30.00) while maintaining a Buy rating.
... MoreXenon Pharmaceuticals (XENE) PT Raised to $44 at Stifel
October 4, 2021 10:39 AM EDTStifel analyst Paul Matteis raised the price target on Xenon Pharmaceuticals (NASDAQ: XENE) to $44.00 (from $31.00) while maintaining a Buy rating.
The analyst commented, "We are reiterating our Buy Rating and updating our price target to $44 to reflect the better-than-expected efficacy... More
Pre-Open Stock Movers 10/04: (XENE) (ADVM) (OSUR) Higher; (MRNA) (NEO) (IIVI) Lower (more...)
October 4, 2021 9:25 AM EDTToday's Pre-Open Stock Movers:
Xenon Pharmaceuticals Inc. (Nasdaq: XENE) 73% HIGHER; reported positive topline results from the Phase 2b X-TOLE clinical trial, which evaluated the clinical efficacy, safety, and tolerability of XEN1101 a differentiated Kv7 potassium channel modulator... More
Xenon's (XENE) X-Tole Data as Good as it Gets with Best-in-Category Efficacy - Analyst
October 4, 2021 8:56 AM EDTEarlier today, Xenon Pharmaceuticals Inc. (Nasdaq: XENE) reported positive topline results from the Phase 2b X-TOLE clinical trial, which evaluated the clinical efficacy, safety, and tolerability of XEN1101 a differentiated Kv7 potassium channel modulator administered as adjunctive treatment in adult patients with focal... More
Xenon Pharmaceuticals (XENE) Phase 2b 'X-TOLE' Clinical Trial of XEN1101 for the Treatment of Focal Epilepsy Met its Primary Efficacy Endpoint
October 4, 2021 7:01 AM EDTXenon Pharmaceuticals Inc. (Nasdaq: XENE), a neurology-focused biopharmaceutical company, today reported positive topline results from the Phase 2b X-TOLE clinical trial, which evaluated the clinical efficacy, safety, and tolerability of XEN1101 a differentiated Kv7 potassium channel modulator administered as adjunctive treatment in adult patients... More
